Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.DSM Biologics and biotechnology firm Crucell NV have signed a license agreement to provide Portuguese company Biotecnol and its US subsidiary with PER.6, a technology used in the development of treatments for infectious disease.
Subscribe to our email newsletter
This license agreement allows Biotecnol to use the PER.C6 human cell line for preclinical and phase I development of its antibody products, which are composed of tribodies and compact antibodies.
“In our opinion, the PER.C6 human cell line is now an established technology. We believe that by adopting the PER.C6 production platform, we will be able to develop our products in a robust, cost efficient and most importantly, in a timely way, due to its characteristics and ease of manipulation,” commented Pedro de Noronha Pissarra, CEO of Biotecnol.
“The deal provides further industrial-leading approval for the use of PER.C6 technology in the development and large scale manufacturing of biologics,” said Arthur Lahr, Crucell’s executive president responsible for sales and business development.
Under the terms of the agreement, Biotecnol will make license payments and annual maintenance fees in exchange for certain rights. Further financial details were not disclosed.